Last reviewed · How we verify

Air O2

University College, London · FDA-approved active Small molecule

Air O2 is a portable oxygen delivery system that provides supplemental oxygen therapy to patients with respiratory insufficiency.

Air O2 is a portable oxygen delivery system that provides supplemental oxygen therapy to patients with respiratory insufficiency. Used for Chronic obstructive pulmonary disease (COPD), Hypoxemia requiring supplemental oxygen therapy.

At a glance

Generic nameAir O2
SponsorUniversity College, London
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhaseFDA-approved

Mechanism of action

Air O2 is a marketed medical device rather than a pharmaceutical drug, designed to deliver oxygen to patients who require respiratory support. It functions as an oxygen concentrator or portable oxygen system that extracts and concentrates oxygen from ambient air for therapeutic inhalation.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: